Skip to main content
OpenTrials
Not yet recruiting

NCT Number: NCT07767890

A Study of the Safety and Effectiveness of Onasemnogene Abeparvovec (Zolgensma) Intrathecal Injection in Spinal Muscular Atrophy Patients

This study aims to assess the safety and effectiveness of onasemnogene abeparvovec intrathecal injection in spinal muscular atrophy (SMA) patients in clinical practice in Japan.

This is a non-interventional study and does not impose a therapy protocol, diagnostic/therapeutic procedure, or a visit schedule. Patients will be treated according to the Japan package insert. Data will be collected using a case registration form (CRF) completed by the investigator at each study site.

Not yet recruiting

Trial opening soon.

Get Notified

Key information

Conditions

Spinal Muscular Atrophy Central Nervous System Diseases Motor Neuron Disease Muscular Atrophy, Spinal Nervous System Diseases Neurodegenerative Diseases Neuromuscular Diseases Spinal Cord Diseases

Age range

2 year and older

Sex eligibility

All sexes

Study type

Observational

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • All patients treated with onasemnogene abeparvovec.

Exclusion criteria

  • Patients who have received onasemnogene abeparvovec for unapproved indications under the Clinical Trials Act or GCP (eg, investigator-initiated clinical trial).

Treatment and study plan

Primary outcomes

  1. Number of Patients With Serious Adverse Events and Adverse Drug Reactions (ADRs)

    Time frame: Up to approximately 4 years and 5 months

  2. Number of Patients With Serious Adverse Events and ADRs Corresponding to the Safety Specifications

    Time frame: Up to approximately 4 years and 5 months

    Safety specifications include hepatotoxicity, transient thrombocytopenia, thrombotic microangiopathy, cardiac adverse events, dorsal root ganglia toxicity/peripheral sensory neuropathy, tumorigenicity due to chromosomal integration, and long-term monitoring of gene therapy.

  3. Incidence of Serious Adverse Events and ADRs

    Time frame: Up to approximately 4 years and 5 months

    Incidence based on the person-year method will be calculated.

  4. Incidence of Serious Adverse Events and ADRs Corresponding to the Safety Specifications

    Time frame: Up to approximately 4 years and 5 months

    Incidence based on the person-year method will be calculated.

  5. Number of Patients by Time to Onset of Serious Adverse Events and ADRs

    Time frame: Up to approximately 4 years and 5 months

  6. Number of Patients by Time to Onset of Serious Adverse Events and ADRs Corresponding to the Safety Specifications

    Time frame: Up to approximately 4 years and 5 months

Secondary outcomes

  1. Change From Baseline in Hammersmith Functional Motor Scale-Expanded (HFMSE) Score

    Time frame: Baseline, 6 months, 12 months, 18 months, 24 months, and every year thereafter, up to approximately 4 years and 5 months

    The HFMSE is a validated SMA specific assessment devised for use in children with SMA to give objective information on motor ability and clinical progression. The HFMSE contains 33 items rated from 0 (unable to perform) to 2 (performs without modification/adaptation/compensation). Total scores range from 0-66. Higher scores indicate higher levels of motor ability.

  2. Change From Baseline in Revised Upper Limb Module (RULM) Score

    Time frame: Baseline, 6 months, 12 months, 18 months, 24 months, and every year thereafter, up to approximately 4 years and 5 months

    RULM is a tool used to assess upper limb function in SMA patients. It consists of 20 items in total. The first entry item classifies overall functional ability and is not scored. The remaining 19 tasks are scored with 1 task scored as can/cannot (1 is the highest score) and 18 tasks rated on a 3-point scale as follows:

    • 0 - unable to perform the task
    • 1 - able to perform the task with some modification
    • 2 - able to perform the task with no difficulty The total RULM score ranges from 0 to 37 with higher scores indicating better upper limb function.

  3. Change From Baseline in Children's Hospital of Philadelphia Infant Test of Neuromuscular Disorders (CHOP-INTEND) Score

    Time frame: Baseline, 6 months, 12 months, 18 months, 24 months, and every year thereafter, up to approximately 4 years and 5 months

    CHOP-INTEND is a tool used to measure the motor abilities in infants with SMA. It consists of 16 items scored on a scale from 0 (no response/unable to perform the movement) to 4 (complete response/able to perform the task). CHOP-Intend total score ranges from 0 to 64 with higher scores indicating higher motor function.

  4. Change From Baseline in Clinical Global Impression-Severity (CGI-S) Score

    Time frame: Baseline, 6 months, 12 months, 18 months, 24 months, and every year thereafter, up to approximately 4 years and 5 months

    The CGI-S scale is a physician-rated measure used to assess the severity of a patient's illness. Severity of illness is assessed with consideration for the overall clinical experience of patients of the same age. The CGI-S scores range from:

    • 0 = Not evaluated
    • 1 = Normal, not at all ill
    • 2 = Borderline normal and ill
    • 3 = Mildly ill
    • 4 = Moderately ill
    • 5 = Markedly ill
    • 6 = Severely ill
    • 7 = Among the most extremely ill

  5. Number of Patients Categorized by Clinical Global Impression-Improvement (CGI-I) Score

    Time frame: 6 months, 12 months, 18 months, 24 months, and every year thereafter, up to approximately 4 years and 5 months

    The CGI-I scale is a physician-rated measure used to assess a patient's overall clinical status. The patient's overall clinical status is scored on a 7-point scale of the extent of change relative to before treatment initiation as follows:

    • 1 = Very much improved
    • 2 = Much improved
    • 3 = Minimally improved
    • 4 = No change
    • 5 = Minimally worse
    • 6 = Much worse
    • 7 = Very much worse Number of patients and their 95% confidence intervals (CIs) will be calculated for two categories: improved (CGI-I score: 1 to 3) and unchanged or worsened (CGI-I score: 4 to 7).

  6. Number of Patients Achieving Each Developmental Milestone

    Time frame: Baseline, 6 months, 12 months, 18 months, 24 months, and every year thereafter, up to approximately 4 years and 5 months

    Developmental milestones include:

    • Sitting without support
    • Hands-and-knees crawling
    • Standing with assistance
    • Walking with assistance
    • Standing alone
    • Walking alone

  7. Number of Patients Maintaining Each Developmental Milestone

    Time frame: Baseline, 6 months, 12 months, 18 months, 24 months, and every year thereafter, up to approximately 4 years and 5 months

Study contacts

Contact information is provided by the study sponsor or research team.

Novartis Pharmaceuticals

CONTACT

[email protected]

+41613241111

Novartis Pharmaceuticals

CONTACT

Sponsors and collaborators

Lead sponsor

Novartis Pharmaceuticals

Industry

Registry information

Official study title

Specified Use-Results Survey of Zolgensma Intrathecal Injection (Spinal Muscular Atrophy)

Important dates

Study start
2026
Primary completion
2031
Study completion
2031
First posted
Aug 17, 2026
Registry last updated
Sep 17, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.